Additionally, our results support previous findings of an uncoupling of amyloid-β deposition and neurodegeneration, beginning in the presymptomatic phases of ADAD, which may partially explain the discordant results of NfL as a biomarker readout across clinical trials that focus on different stages of the disease and AD populations. This evidence concerns the gene NEFL and Alzheimer disease.